Retatrutide: What Trial Doses, Routes, and Pharmacokinetics Were Studied

The short version: doses studied in trials

Retatrutide has been studied only as an investigational drug in clinical trials. The doses used are reported here as study-design facts — what researchers administered in a controlled, supervised setting — not as guidance for any person's use. Retatrutide has no approved formulation, no prescription dose, and no approved reconstitution protocol. In the Phase 2 obesity trial, the dose range studied was 1, 4, 8, and 12 mg once weekly by subcutaneous (under-skin) injection over 48 weeks. In Phase 1b, doses started as low as 0.5 mg and escalated up to 12 mg weekly. The half-life — how long the compound stays active before the body clears half of it — is approximately 6 days, which is why once-weekly dosing worked in trials. The trial record covers what doses were administered, how they were escalated, and what results were measured. It does not cover what any individual should take.

Retatrutide dosage in Phase 1b

The first-in-human trial (Urva et al., Lancet, 2022) studied the following subcutaneous once-weekly doses in 72 adults with type 2 diabetes over 12 weeks ^[4]:

• 0.5 mg once weekly (fixed)
• 1.5 mg once weekly (fixed)
• 3 mg once weekly (fixed)
• 3 mg escalating to 6 mg
• 3 mg escalating to 6 mg, then 9 mg, then 12 mg

All arms were administered subcutaneously once weekly. The escalation protocol was used to assess tolerability as doses increased. The highest-dose group (the 3/6/9/12 mg escalation arm) showed placebo-adjusted weight loss of −8.96 kg over 12 weeks ^[4]. Daily mean glucose was reduced by −2.8 mmol/L at the 3 mg level ^[4].

Retatrutide dosage in Phase 2 obesity and diabetes trials

Phase 2 obesity (Jastreboff et al., 2023): 1, 4, 8, and 12 mg subcutaneous once weekly for 48 weeks. Doses were fixed (not escalated) within arms; participants were randomized to one dose level ^[1].

Phase 2 type 2 diabetes (Rosenstock et al., 2023): Starting dose 0.5 mg, escalated stepwise to 12 mg over the 36-week trial. The escalation schedule allowed tolerability assessment across a wide dose range and was overseen by clinical trial staff ^[2].

In both trials, dose selection and escalation were managed by clinical investigators. GI adverse events — nausea, vomiting, diarrhea — were dose-related and the primary driver of dose discontinuation at the highest levels ^[1][2].

Retatrutide half life

Phase 1b pharmacokinetic data establish retatrutide's half-life (the time for blood concentration to fall by half) at approximately 6 days ^[4]. This extended half-life results from the C20 fatty-diacid acylation (a chemical modification that attaches the peptide to albumin — the most abundant protein in blood — and slows its clearance from circulation). Once-weekly subcutaneous dosing was selected based on this PK profile. A 6-day half-life means that after stopping, the compound remains pharmacologically active for several weeks before clearing.

Route of administration studied

All Phase 1, 2, and 3 trials of retatrutide have used subcutaneous injection — delivery into the fatty tissue just beneath the skin — administered once weekly ^[1][2][4]. No oral, intravenous, or intramuscular formulations have been reported in the clinical record as of mid-2026. The exact injection site (abdomen, thigh, upper arm) was not specified uniformly across all trial protocols.

Retatrutide stability and storage context

Retatrutide has been studied only as a clinical-trial investigational product administered by a healthcare professional under clinical conditions. No approved formulation standard, storage protocol, or stability specification exists for any non-trial preparation ^[2]. The stability notes in the trial record are proprietary to Eli Lilly's investigational drug master file; they have not been published.

How to reconstitute retatrutide

There is no published, validated reconstitution protocol for retatrutide. It is an investigational compound with no approved formulation. In clinical trials, retatrutide was provided by the manufacturer as a pre-prepared solution for subcutaneous injection — it was not reconstituted at the site. Gray-market research-labeled vials may require reconstitution, but no standard exists, and such material has not been verified for identity, purity, or sterility ^[1]. Publishing a reconstitution recipe for an unregulated, unapproved injectable compound would be irresponsible and goes beyond the editorial remit of this site.

Retatrutide cost

Retatrutide has no approved price because it has no approved indication. It is not available by prescription. No manufacturer list price, insurance coverage, or pharmacy acquisition cost exists for retatrutide as of mid-2026. Comparable approved incretin-class agents have carried annual list prices in the tens of thousands of dollars in the United States prior to insurance coverage and manufacturer programs. What retatrutide would cost upon approval — and what access pathways would exist — is speculative until Phase 3 outcomes drive regulatory and commercial decisions. Gray-market pricing for research-labeled material varies widely and reflects unregulated supply chains, not pharmaceutical pricing standards.